K McKenna
Beaumont Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by K McKenna.
Diabetic Medicine | 2001
K McKenna; Diarmuid Smith; Kb Moore; A. Glen; William Tormey; Christopher J. Thompson
Atrial natriuretic peptide (ANP) increases urinary albumin excretion in Type 1 diabetes mellitus (DM). Brain natriuretic peptide (BNP) is structurally and functionally related to ANP, but its effect on urine albumin excretion rate (UAER) is unknown.
Irish Journal of Medical Science | 2005
K McKenna; Diarmuid Smith; Mark Sherlock; Kb Moore; E. O’Brien; William Tormey; Christopher J. Thompson
BackgroundThe intravenous infusion of atrial (ANP) and brain (BNP) natriuretic peptides have been shown to increase urinary albumin excretion in type 1 diabetes.AimsTo measure plasma ANP and BNP concentrations in patients with type 1 diabetes and to examine the parameters associated with elevated plasma concentrations.MethodsWe measured plasma ANP and BNP concentrations, UAER, HbA1C systolic blood pressure, and left ventricular mass index. Plasma ANP and BNP were also measured in non-diabetic control subjects for comparison.ResultsUsing multivariate regression analysis plasma ANP correlated positively with HbA1C (1.9 + 0.47, p = 0.0002), UAER (0.37+ 0.05, p =0.00001), SBP (1.26 + 0.5, p = 0.01) and LVMI (0.46 + 0.25, p = 0.07). BNP was positively related with LVMI (0.95 + 0.4, p = 0.02), and UAER (0.56 + 0.08, p = 0.001).ConclusionsPlasma concentrations of ANP and BNP are elevated in some patients with type 1 diabetes. Plasma ANP concentrations are closely related to UAER and elevated plasma concentrations are associated with poor glycaemic control and systemic hypertension. Plasma BNP concentration is related to LVMI.
Diabetic Medicine | 2000
K McKenna; Diarmuid Smith; P. Barrett; A. Glenn; C. M. Kesson; John M. C. Connell; Christopher J. Thompson
Aims This study examined the effect of angiotensin‐converting enzyme inhibition, administered at doses with no effect on systemic blood pressure, on the albuminuric action of atrial natriuretic peptide (ANP).
Diabetic Medicine | 2000
K McKenna; Diarmuid Smith; Kb Moore; A. Glen; C. M. Kesson; Christopher J. Thompson
Aims To ascertain whether intravenous infusion of atrial natriuretic peptide (ANP) can induce microalbuminuria in patients with Type 1 diabetes mellitus (DM), as already demonstrated in patients with microalbuminuria, and to compare the albuminuric response to ANP infusion in Type 1 DM and a matched group of healthy non‐diabetic controls.
The Journal of Clinical Endocrinology and Metabolism | 2002
Diarmuid Smith; K McKenna; Kb Moore; William Tormey; J Finucane; Jack Phillips; P. H. Baylis; Christopher J. Thompson
Irish Journal of Medical Science | 2007
Kb Moore; K McKenna; M Osman; William Tormey; D McDonald; Christopher J. Thompson
Irish Journal of Medical Science | 1998
A. Gleeson; D. Owens; P. Collins; A. Johnson; Gerald H. Tomkin; D. M. Sexton; G. Creedon; M. Ledwith; M. Griffin; N. O’Meara; M. T. Kilbane; A. M. Tuite; S. G. Shering; D. Smith; F. W. M. McDermott; N. J. O’Higgins; P. P. A. Smyth; K McKenna; C. J. Thompson; W. M. Kohler; D. O’Shea; J. Alaghband-Zadeh; K. Latham; Gregory Carter; Enda W. McDermott; S. L. Lovell; H. Leslie; C. Doherty; D. R. Hadden; Mary G. McGeown
Irish Journal of Medical Science | 1998
W. J. Kokaly; T. J. McKenna; W. M. Kong; D. O’sShea; J. Alaghband-Zadeh; J. Jones; G. Carter; P. P. A. Smyth; Colm O’Herlihy; J. H. Lazarus; L. D. K. E. Premawardhana; A. B. Parkes; C. S. Kularatna; A. Rees; J. Evans; C. Wijeyaratne; H. Da Silva; A. Gleeson; K. Anderton; D. Owens; P. Collins; A. Johnson; Gerald H. Tomkin; D. Smith; Francis M. Finucane; K McKenna; J. Finucane; C. J. Thompson; J. P. Phillips; E. M. McConnell
Archive | 2002
Kb Moore; K McKenna; D McDonald; William Tormey; Christopher J. Thompson
Archive | 2002
Kb Moore; K McKenna; D McDonald; William Tormey; Christopher J. Thompson
